Finasteride is an FDA-approved 5-alpha-reductase inhibitor used primarily for benign prostatic hyperplasia and androgenic alopecia in men. It works by lowering dihydrotestosterone (DHT) through inhibition of 5-alpha-reductase isoenzymes. Finasteride 5 mg was first used in 1992 for BPH, and 1 mg was approved in 1997 for male pattern hair loss.
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
KilgourMD announced phase II clinical trial results showing 53% of menopausal women with hair loss achieved meaningful regrowth within four months, with a 60% reduction in hair shedding.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07742553 |
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT06944145 |
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia |
RECRUITING | PHASE2 |
| NCT06601205 |
Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer. |
COMPLETED | PHASE2/PHASE3 |
| NCT05990400 |
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia |
UNKNOWN | PHASE2/PHASE3 |
| NCT04848181 |
The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate |
COMPLETED | EARLY_PHASE1 |
| NCT04288427 |
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy |
RECRUITING | NA |
| NCT03004469 |
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia |
COMPLETED | PHASE3 |
| NCT02781311 |
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males |
COMPLETED | PHASE2 |
| NCT02703220 |
Sleep Apnea in Elderly |
RECRUITING | PHASE4 |
| NCT02548117 |
H-36731: Finasteride in Management of Elevated Red Blood Cells |
WITHDRAWN | PHASE3 |
